Larazotide

The speaker notes that peptides and LDN are used under medical supervision within their functional medicine program, implying these are not over-the-counter or self-administered protocols. This is the only safety-adjacent statement made regarding peptide use in the video — no contraindications, side effects, or drug interactions are discussed. The speaker positions medical oversight as a key differentiator of their clinic's approach versus self-directed protocols.

The speaker frames peptides (alongside LDN) as advanced tools that 'most specialists have never heard of,' positioning them as a distinguishing feature of functional medicine practice versus conventional care. The cost of LDN ($30–$90/month from compounding pharmacies) is mentioned as context for accessibility, though no peptide pricing is given. This framing serves as both a clinical observation and a marketing claim. No safety warnings or contraindications are discussed for the peptides.

The speaker explicitly distinguishes the mechanisms of peptides from those of LDN, stating that 'no peptides can do what LDN does' in targeting central nervous system inflammation via microglial pathways. This implies the peptides in the stack are viewed as complementary rather than interchangeable with LDN, each filling a different mechanistic role (gut lining, NF-κB, tight junctions vs. CNS immune modulation). No dosages are specified. This framing positions the combined protocol as superior to any single agent.

The speaker describes layering the peptide stack (BPC-157, KPV, Larazotide) on top of Low Dose Naltrexone (LDN) and micro-dosed GLP-1 medications as a potent combined anti-inflammatory protocol. The GLP-1 micro-dosing is explicitly noted as being used for anti-inflammatory purposes rather than weight loss or diabetes management. No specific peptide dosages are given, though GLP-1 escalation from 2.5 to 10 mg over 6 months is mentioned in a patient case. This is presented as the clinic's advanced multi-system approach.

The speaker makes a broad claim early in the video that peptides can 'turn off inflammation at a genetic level,' framing this as a distinguishing feature of the clinical tools used in their practice. This claim is most directly supported by the subsequent description of KPV's NF-κB inhibition mechanism, which operates at the level of gene transcription. No specific dosages or study citations are provided for this overarching claim. It is presented as a key differentiator from standard dietary interventions.

The speaker describes a three-peptide clinical stack combining BPC-157, KPV, and Larazotide as a coordinated approach to gut and systemic inflammation. Each peptide is said to address a distinct mechanism: BPC-157 heals the gut lining and boosts antioxidants, KPV blocks NF-κB inflammatory gene activation, and Larazotide repairs tight junctions and the zonulin pathway. No individual or combined dosages are specified. This stack is presented as a standard clinical protocol in the speaker's functional medicine clinic.

Larazotide (transcribed as 'laorazzide') is described as directly targeting tight junctions in the gut lining — the cellular seals that, when loosened, produce the condition known as leaky gut. The speaker specifically references the zonulin pathway as a key mechanism, noting that zonulin is a protein that becomes dysfunctional in leaky gut and that larazotide addresses intestinal permeability at the mechanistic level. No dosage is mentioned. Presented as a clinical tool.

Dr. Jones outlines a three-pillar protocol for autoimmune conditions: (1) root cause functional medicine addressing gut, inflammation, nutrients, diet, and nervous system; (2) advanced tools including low-dose naltrexone, anti-inflammatory diet, and therapeutic peptides (BPC-157, KPV, Larazotide, Thymosin Alpha-1, GLP-1s); (3) medical oversight. He emphasizes that most programs only offer one or two of these pieces, and all three are needed for success.

As part of a layered functional medicine protocol for autoimmune conditions, Dr. Jones recommends peptides BPC-157 ('BPC57' as spoken), KPV, and Larazotide specifically for gut repair and reducing systemic inflammation. These are positioned as advanced tools used after foundational interventions (gut health, anti-inflammatory diet, nutrient repletion) are in place. No specific dosages are provided.